Talis Biomedical Corporation Revenue and Competitors

Claim your profile

Location

$8.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Talis Biomedical Corporation's estimated annual revenue is currently $42.9M per year.(i)
  • Talis Biomedical Corporation's estimated revenue per employee is $192,534
  • Talis Biomedical Corporation's total funding is $8.6M.

Employee Data

  • Talis Biomedical Corporation has 223 Employees.(i)
  • Talis Biomedical Corporation grew their employee count by -7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings. Our visionary team combines depth of experience with passion to deliver a pioneering solution to infectious disease diagnostics. Infectious disease treatment today is largely guideline-driven: treat patients with similar symptoms the same. Unfortunately, similar symptoms can often have very different causes. Our tests will enable caregivers to know within minutes, the cause of illness, as well as which medications will be effective for their patient, empowering them to provide individualized care rather than broad, guideline-dictated treatments. From the doctor's office to the hospital bedside to remote care settings, we are re-defining the treatment of infectious diseases.

keywords:Biotechnology,Healthcare

$8.6M

Total Funding

223

Number of Employees

$42.9M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Talis Biomedical Corporation News

2022-04-17 - Insiders who purchased Talis Biomedical Corporation (NASDAQ:TLIS) earlier this year lose an additional US$180k as the stock sinks to US$1.15

Insiders who purchased Talis Biomedical Corporation (NASDAQ:TLIS) earlier this year lose an additional US$180k as the stock sinks to US$1.15.

2022-04-17 - Insiders who purchased Talis Biomedical Corporation (NASDAQ:TLIS) earlier this year lose an additional US$180k as the stock sinks to US$1.15

Insiders who purchased Talis Biomedical Corporation (NASDAQ:TLIS) earlier this year lose an additional US$180k as the stock sinks to US$1.15.

2022-03-22 - Talis Biomedical Provides Business Update and Reports ...

MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health...

2022-03-22 - Talis Biomedical Provides Business Update and Reports ...

MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health...

2020-11-12 - Talis Expands Executive Team and Closes Additional Financing in Preparation for Commercial Launch of Talis One™ System

MENLO PARK, Calif., Nov. 12, 2020 /PRNewswire/ -- Talis Biomedical Corporation, a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point of care, today announced it has strengthened its executive management team with the appointment of Rob Ke ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35.9M22510%N/A
#2
$74.3M2339%N/A
#3
$56.1M23723%N/A
#4
$55.5M24631%$178M
#5
$75M25510%N/A